Changli Wang

5.4k total citations
29 papers, 522 citations indexed

About

Changli Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Changli Wang has authored 29 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Changli Wang's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Diagnosis and Treatment (16 papers) and Lung Cancer Research Studies (9 papers). Changli Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Diagnosis and Treatment (16 papers) and Lung Cancer Research Studies (9 papers). Changli Wang collaborates with scholars based in China, United States and France. Changli Wang's co-authors include Zhongli Zhan, Leina Sun, Dongsheng Yue, Baocun Sun, Qiang Zhang, Haiquan Chen, Weimin Mao, Chun Chen, Shidong Xu and Yi Shen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Changli Wang

27 papers receiving 511 citations

Peers

Countries citing papers authored by Changli Wang

Since Specialization

Citations

This map shows the geographic impact of Changli Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changli Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changli Wang more than expected).

Fields of papers citing papers by Changli Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changli Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changli Wang. The network helps show where Changli Wang may publish in the future.

Co-authorship network of co-authors of Changli Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Changli Wang. A scholar is included among the top collaborators of Changli Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changli Wang. Changli Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extraction and purification, structural characteristics, biological activities, applications, and quality control of Aloe vera polysaccharides: A review 2025 ·International Journal of Biological Macromolecules ·Duo Li, Hongwei Wang, A. Dong, Qiao Zhang, Changli Wang, Jing Wang, Jing Sun, Chongbo Zhao	0
2	Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis 2025 ·BMC Medicine ·(unknown), (unknown), (unknown), Yan Liang, Chun Huang, Fuchao Chen, (unknown), Song Xia, Cuimin Ding, Changli Wang, Richeng Jiang	0
3	Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer 2024 ·Annals of Surgical Oncology ·Weiran Liu, Chen Chen, Chenguang Li, Xinyi Wu, Yuchen Ma, (unknown), Dingli Wang, (unknown), Xue Zheng, Zhenfa Zhang, Changli Wang, Dongsheng Yue, Bin Zhang	1
4	Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report 2022 ·Frontiers in Oncology ·Yu Zhang, Hao Zhang, Hanqing Wang, (unknown), Bo Zhang, Ning Zhou, Lingling Zu, Zuoqing Song, Changli Wang, Song Xu	1
5	Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib 2021 ·Translational Lung Cancer Research ·Jingjing Li, Bin Zhang, Yu Zhang, Feng Xu, Zhenfa Zhang, Lin Shao, (unknown), Paola Ulivi, Marc G. Denis, Petros Christopoulos, Vincent de Montpréville, Eric Bernicker, Anthonie J. van der Wekken, Changli Wang, Dongsheng Yue	13
6	Macroseismic intensity attenuation in western China 2021 ·Journal of Seismology ·(unknown), Changli Wang, (unknown), (unknown), Jigang Zhang	3
7	Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis 2020 ·Translational Lung Cancer Research ·Bin Zhang, Lianmin Zhang, Dongsheng Yue, Chenguang Li, Hua Zhang, Junyi Ye, Liuwei Gao, Xiaoliang Zhao, Chen Chen, (unknown), Chong Pang, Yue Li, Yulong Chen, Shannon Chuai, Zhenfa Zhang, Giuseppe Giaccone, Changli Wang	12
8	Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway 2018 ·OncoTargets and Therapy ·Hui Chen, Qiang Zhang, Yu Zhang, (unknown), Bin Zhang, Changli Wang	10
9	EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors 2018 ·Diagnostic Pathology ·Chenguang Li, Rui Jia, Hailin Liu, Bin Zhang, Changli Wang	15
10	Cisplatin resistance in lung cancer is mediated by <italic>MACC1</italic> expression through PI3K/AKT signaling pathway activation 2018 ·Acta Biochimica et Biophysica Sinica ·Qiang Zhang, Bin Zhang, Leina Sun, (unknown), Yu Zhang, Zhenfa Zhang, Yanjun Su, Changli Wang	14
11	Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors 2018 ·Journal of Cancer Research and Clinical Oncology ·Chenguang Li, Hailin Liu, Bin Zhang, (unknown), Yanjun Su, Zhenfa Zhang, Changli Wang	10
12	Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial 2018 ·The Lancet Respiratory Medicine ·Dongsheng Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lanjun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Changli Wang	177
13	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study 2015 ·Japanese Journal of Clinical Oncology ·Yi-Sheng Huang, Li Zhang, Yuankai Shi, Shenglin Ma, Meilin Liao, Chunxue Bai, Qingyuan Zhang, Changli Wang, Feng Luo, Shiying Yu, Shukui Qin, Xiuyi Zhi, Caicun Zhou	5
14	Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer 2014 ·PLoS ONE ·Chenguang Li, (unknown), Yue Li, Shengguang Wang, Hui Chen, Lianmin Zhang, Bin Ke, (unknown), (unknown), Bingsheng Sun, Bin Zhang, Changli Wang	19
15	Validation of EORTC QLQ-LC43 for Chinese patients with lung cancer 2014 ·Lung Cancer ·Lei Zhang, Yanjun Su, (unknown), Weiran Liu, Lin Yue, (unknown), Le Luo, Wei‐Dong Lü, Stephanie Woo, Adam R. Miller, Shumin Xie, Hong Zhu, Chong Pang, Jing Zhang, Changli Wang	12
16	[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. 2013 ·PubMed ·Xu‐Chao Zhang, (unknown), Li Zhang, Changli Wang, Ying Cheng, Gan‐di Li, Tony Mok, Cheng Zhi Huang, Xiaoqing Liu, Jie Wang, Mengzhao Wang, Yiping Zhang, Jianying Zhou, (unknown), Dongmei Lin, Jin‐Ji Yang, Hui Li, Haiquan Chen, Wen‐Zhao Zhong, Yi‐Long Wu	22
17	Short-term Response and Toxicity of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer 2012 ·Changli Wang	1
18	Expression and prognostic value of TTF-1 and CK in small cell lung carcinoma 2012 ·Clinical Oncology and Cancer Research ·(unknown), (unknown), (unknown), Baocun Sun, Changli Wang	2
19	Development of molecular-targeted therapy for non-small cell lung cancer 2011 ·Clinical Oncology and Cancer Research ·(unknown), Changli Wang	1
20	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice 2011 ·Journal of Experimental & Clinical Cancer Research ·Leina Sun, Qiang Zhang, (unknown), Zhongli Zhan, Changli Wang, Baocun Sun	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact